. Author manuscript; available in PMC: 2018 Mar 1.

Published in final edited form as: J Allergy Clin Immunol Pract. 2016 Sep 21;5(2):410–419.e4. doi: 10.1016/j.jaip.2016.08.001

TABLE II.

Clinical outcomes

Outcome	Controlled severe asthma (N = 15)		Achieved control with triamcinolone (N = 24)		Did not achieve control with triamcinolone (N = 17)
Outcome	Baseline	After triamcinolone	Baseline	After triamcinolone	Baseline	After triamcinolone
AQLQ score^*	6.4 (5.9–6.6)	6.6^† (6.5–6.9)	5.2 (4.1–5.9)	6.3^‡ (5.4–6.6)	4.9 (3.9–5.5)	5.0 (4.1–5.8)
Blood eosinophils (%)^§	7.9 (5.5–10.3)	1.7^* (1.0–3.3)	5.4 (3.8–8.9)	2.1^‡ (1.0–2.2)	5.8 (3.9–10.0)	2.6^* (1.2–3.3)
Exhaled nitric oxide (ppb)^§	28 (11–58)	13^‡ (8–19)	25 (19–77)	16^‡ (11–25)	36 (21–46)	26^‖ (15–42)
FEV₁ (% predicted)	95 (84–105)	99^‖ (86–129)	89 (71–97)	92^‖ (86–97)	86 (74–103)	79 (75–89)

IQR, Interquartile range.

Data are from participants who completed the study. Values represent the median (IQR).

Maximum score on the AQLQ is 7, with higher scores representing greater asthma-related quality of life.

^†

P < .01 vs baseline.

^‡

P < .001 vs baseline.

^§

Data were logarithmically transformed before analysis.

^‖

P < .05 vs baseline.